Drug Trial Radar · NCT04964986
Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jun 14, 2021
Primary completion
Jun 6, 2023
Study completion Jun 6, 2023
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.
Conditions
- Short Bowel Syndrome
Interventions
ApraglutideDrug
Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Treatment-Emergent Adverse Event (TEAE)Time frame: Day 1 up to approximately 55 weeks
- Absolute Change in Absorption of Energy Over Metabolic Balance (MB) Periods From Baseline at Week 48Time frame: Baseline and Week 48
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
UZ Leuven
Leuven, Belgium
Beaujon Hospital
Clichy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.